Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Arun Azad

Peter MacCallum Cancer Institute

Research Interests

Explore related searches

Articles (20)

Collaborators (9)

Andrew Armstrong

Duke Cancer Institute

UNITED STATES

Christof Vulsteke

University of Antwerp

Vinod Vijay Subhash

University of New South Wales

Maha Hussain

Northwestern University

UNITED STATES

Anthony M. Joshua

Head of Department

University Health Network

Ben Tran

Peter MacCallum Cancer Institute

Pingfu Fu

Case Western Reserve University

UNITED STATES

Michael Hofman

Peter MacCallum Cancer Institute

Shahneen Sandhu

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Arun Azad

Research Interests

Explore related searches

Articles (20)

Collaborators (9)

Andrew Armstrong

Christof Vulsteke

Vinod Vijay Subhash

Maha Hussain

Anthony M. Joshua

Ben Tran

Pingfu Fu

Michael Hofman

Shahneen Sandhu

Make your next move.

Arun Azad

Research Interests

Explore related searches

Articles (20)

AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial

Guideline of guidelines: lutetium‐177 PSMA radioligand therapy in advanced prostate cancer

Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer

Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01

From salvage to spotlight: how 2025 transformed PSMA radioligand therapy

Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.

Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

Pembrolizumab in metastatic hormone-sensitive prostate cancer: lessons from the negative KEYNOTE-991 trial.

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

Prognostic Value of Restaging [ 18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [ 177Lu]Lu-PSMA-617 Therapy.

Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial.

Collaborators (9)

Andrew Armstrong

Christof Vulsteke

Vinod Vijay Subhash

Maha Hussain

Anthony M. Joshua

Ben Tran

Pingfu Fu

Michael Hofman

Shahneen Sandhu

Make your next move.